Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent/destructive annotations, the description discloses graceful degradation when GLEIF/OpenFIGI is unavailable, internal cascading through multiple lookup endpoints, explicit `unresolved` reporting instead of silent omission, and ambiguous-match behavior returning `figi_candidates`. This is rich behavioral context the annotations alone do not provide.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with common user phrasings and a clear directive, and every clause carries useful information. It is long and dense, with large parentheticals, but the complexity of the tool justifies most of the length; a little more structuring would make it easier to scan.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's complexity, two entity types, and multiple backing sources, the description covers edge cases such as ambiguous bonds, non-US issuers, unresolved identifiers, and degraded enrichment. Even without an output schema, it tells the agent what to expect in ambiguous and failure cases, making it complete enough to invoke correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although the schema already describes both parameters, the description adds critical semantic guidance: accepted input formats like ticker versus CIK versus ISIN, brand versus generic drug names, and a concrete warning to pass only the entity name for bonds, with an example showing why trailing security-class words fail. This materially improves correct invocation.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb and resource: resolve a user-spoken name to the canonical/official identifiers other tools require. It also distinguishes itself from siblings by positioning it as the first step whenever a name needs to become an ID, and by listing the two supported entity types with their exact identifier outputs.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit usage direction with 'Use FIRST whenever you have a name but need an ID' and explains what inputs it accepts. It does not explicitly name alternative tools to avoid, but the clear context and priority instruction are strong enough for an agent to select it correctly.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.1/5.0
Disambiguation2/5

Many tools have overlapping research purposes (ask_pipeworx, deep_research, ask_pipeworx_grounded) and multiple bet-related tools (bet_research, polymarket_arbitrage, polymarket_edges). Reactome-specific tools are few but mixed in with unrelated tools, causing ambiguity.

Naming Consistency2/5

Tool names are inconsistent: some snake_case (ask_pipeworx, deep_research), some camelCase (generate_llms_txt, list_subscriptions), and some mixed (pipeworx_feedback, poly market_arbitrage). No uniform pattern.

Tool Count2/5

35 tools is excessive for a Reactome server, as only a handful are Reactome-specific. Many tools are unrelated (e.g., bet_research, compare_entities), making the tool count feel bloated and unfocused.

Completeness2/5

The Reactome-specific tools cover basic pathway lookups but miss key operations like reactions, complexes, or advanced queries. The server's completeness for the Reactome domain is poor, diluted by many non-Reactome tools.